Formycon AG and OneSource Specialty Pharma Limited announced a strategic manufacturing partnership for biosimilars, combining Formycon's development expertise with OneSource's integrated drug substance and drug product manufacturing capabilities at its biologics facility in Bangalore, India. The collaboration aims to support Formycon's biosimilar programs for global markets, emphasizing reliable, scalable, and cost-efficient production as a cornerstone of Formycon's FYB4Growth strategy.
Dr. Stefan Glombitza, CEO of Formycon AG, stated: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies."
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, commented: "We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics."
The partnership reflects a shared commitment to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model, which OneSource is positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
Formycon's FYB4Growth strategy is built on four pillars: geographic diversification into high-growth regions, a smart portfolio strategy combining blockbuster molecules with niche products, excellence and innovation in technological and regulatory development, and consistent cost efficiency through streamlined processes and digital technologies. More details can be found at FYB4Growth.
OneSource Specialty Pharma is a pure-play global CDMO focusing on complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies. It operates five state-of-the-art manufacturing facilities approved by global regulatory authorities and has a dedicated team of over 1,600 professionals. Further information is available at OneSource CDMO.
Biosimilars are successor products to biopharmaceutical drugs whose patents have expired, and they are approved in highly regulated markets such as the EU, USA, Canada, Japan, and Australia. They create competition, expand patient access to biopharmaceutical therapies, and reduce healthcare costs. Global biosimilar sales currently amount to around $21 billion, with analysts projecting a rise to over $74 billion by 2030.
